AU2002365847A1 - Use of alkanoyl l-carnitine for the treatment of erectile dysfunction - Google Patents

Use of alkanoyl l-carnitine for the treatment of erectile dysfunction

Info

Publication number
AU2002365847A1
AU2002365847A1 AU2002365847A AU2002365847A AU2002365847A1 AU 2002365847 A1 AU2002365847 A1 AU 2002365847A1 AU 2002365847 A AU2002365847 A AU 2002365847A AU 2002365847 A AU2002365847 A AU 2002365847A AU 2002365847 A1 AU2002365847 A1 AU 2002365847A1
Authority
AU
Australia
Prior art keywords
carnitine
erectile dysfunction
alkanoyl
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002365847A
Other languages
English (en)
Inventor
Aleardo Koverech
Andrea Lenzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2002365847A1 publication Critical patent/AU2002365847A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2002365847A 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction Abandoned AU2002365847A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2001A000708 2001-12-04
IT2001RM000708A ITRM20010708A1 (it) 2001-12-04 2001-12-04 Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
PCT/IT2002/000758 WO2003047563A1 (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
AU2002365847A1 true AU2002365847A1 (en) 2003-06-17

Family

ID=11455907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002365847A Abandoned AU2002365847A1 (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction

Country Status (16)

Country Link
US (3) US20050080018A1 (enExample)
EP (1) EP1450782B9 (enExample)
JP (1) JP4370169B2 (enExample)
KR (1) KR100907938B1 (enExample)
AT (1) ATE309800T1 (enExample)
AU (1) AU2002365847A1 (enExample)
CA (1) CA2465471C (enExample)
DE (1) DE60207442T2 (enExample)
DK (1) DK1450782T3 (enExample)
ES (1) ES2250749T3 (enExample)
HU (1) HU229214B1 (enExample)
IT (1) ITRM20010708A1 (enExample)
MX (1) MXPA04005269A (enExample)
PL (1) PL211211B1 (enExample)
SI (1) SI1450782T1 (enExample)
WO (1) WO2003047563A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040561A1 (it) 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ­２ 억제제
IT1397867B1 (it) * 2010-02-03 2013-02-04 Brotzu Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
US20180104268A1 (en) * 2015-04-30 2018-04-19 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
WO2018087132A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
EP0793962B1 (en) * 1996-03-04 1999-12-08 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Medicament containing a carnitine derivative for treating arteriosclerosis obliterans
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
IT1293539B1 (it) * 1997-07-16 1999-03-01 Sigma Tau Ind Farmaceuti Composizione nutritiva per soggetti in stato di debilitazione causato da stress
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6241471B1 (en) * 1999-08-26 2001-06-05 General Electric Co. Turbine bucket tip shroud reinforcement
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di

Also Published As

Publication number Publication date
SI1450782T1 (sl) 2006-02-28
EP1450782B1 (en) 2005-11-16
JP2005511655A (ja) 2005-04-28
DE60207442T2 (de) 2006-07-27
US20070117762A1 (en) 2007-05-24
MXPA04005269A (es) 2004-10-11
ES2250749T3 (es) 2006-04-16
ITRM20010708A1 (it) 2003-06-04
US20050080018A1 (en) 2005-04-14
CA2465471C (en) 2010-10-19
US20120041005A1 (en) 2012-02-16
KR100907938B1 (ko) 2009-07-16
KR20050044594A (ko) 2005-05-12
HU229214B1 (hu) 2013-09-30
WO2003047563A1 (en) 2003-06-12
EP1450782A1 (en) 2004-09-01
DE60207442D1 (de) 2005-12-22
ITRM20010708A0 (it) 2001-12-04
PL371131A1 (en) 2005-06-13
HUP0402062A3 (en) 2012-09-28
JP4370169B2 (ja) 2009-11-25
ATE309800T1 (de) 2005-12-15
CA2465471A1 (en) 2003-06-12
PL211211B1 (pl) 2012-04-30
HUP0402062A2 (hu) 2005-02-28
US8343979B2 (en) 2013-01-01
DK1450782T3 (da) 2006-02-20
EP1450782B9 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
TW200505434A (en) Therapeutic treatment
CA102009S (en) Bottle
CA98438S (en) Spout
CA97230S (en) Escutcheon
MXPA03010655A (es) Gel oft??lmico de pirenzepina.
CA97229S (en) Escutcheon
CA96618S (en) Beer cask with tap
TWD103219S1 (zh) 燈
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
SI1450782T1 (sl) Uporaba kombinirane zmesi, ki vsebuje propionil L-karnitin in dodatna zdravila za zdravljenje erektivne disfunkcije
AU2003214110A1 (en) 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
MY146794A (en) Use of an alpha-2-delta ligand for the treatment of luts
SG139747A1 (en) Inhibitors of the mutant form of kit
AU2003253498A1 (en) Shower device with tanning device and method for use thereof
AU2003249554A1 (en) Process and device for the treatment of water, particularly for ships
AU2001274649A1 (en) Topical preparation of alprostadil for the treatment of erectile dysfunction
HUP0301828A3 (en) Use of apomorphine for the production of pharmaceutical compositions for treating sexual dysfunction with apomorphine at specified plasma concentration levels
CA97520S (en) Door handle
EP1072661A3 (en) A silicone coating composition for a shatter-resistant incandescent lamp
NO20052557D0 (no) Morfolinderivater for bruk som dopamin-agonister i behandling av blant annet seksuell dysfunksjon.
AU5716800A (en) Process for the hydrogenation of a polymer composed of diene monomer units and anitrile group-containing monomer units
AU2002365288A1 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
AU2003231803A1 (en) Treatment of cancer with mefloquire
CA97177S (en) Faucet
CA97879S (en) Faucet

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase